Jeito Capital has confirmed the final close of its second fund, Jeito II, at a record $1.2 billion. The Paris-based private equity firm exceeded its original target, marking a significant moment for the European life sciences sector. This latest round means the firm has tripled its assets under management to €1.6 billion in only five years. The fund is now one of the largest independent vehicles in Europe dedicated entirely to the Biopharma industry.
The new capital will be used to back between 15 and 20 clinical-stage companies. Jeito intends to focus on firms developing treatments for severe diseases where there is a high level of unmet patient need. By increasing the size of its individual investments up to €150 million, the fund will help these businesses move through advanced clinical trials and reach the commercial market. Capital has already been allocated to several key areas, including obesity, oncology and autoimmune diseases.
Dr Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital, said: “The closing of Jeito II at more than one billion euros represents a very significant milestone for our business. This record fundraising is a collective success, reflecting the dedication and expertise of the entire Jeito team, the talent of its portfolio companies’ managers and the trust of our investors. We would like to thank them all for their hard work, dedication and support. It is also a strong signal for the European Biopharma ecosystem, demonstrating the growing conviction that European companies can drive major therapeutic innovation and significant economic benefits with the appropriate access to financial and strategic resources.”
The firm’s strategy arrives as the global pharmaceutical industry faces a major patent cliff. Reports suggest that expiring patents could lead to a $400 billion drop in industry revenues by 2033. This shift is driving larger pharmaceutical companies to look toward smaller Biopharma firms for new innovation. Jeito has already seen success with this model, noting three recent exits including the acquisitions of EyeBio and Hi-Bio by Merck & Co and Biogen.
Sabine Dandiguian, Managing Partner at Jeito Capital, added: « Jeito II continues a disciplined and proven strategy built around a clear conviction: some of the most compelling opportunities in Biopharma lie at the intersection of scientific excellence, strong unmet medical need and growing demand for differentiated innovation. In this environment, value creation requires both selectivity and continuity, backing the best companies, at the right time, with the right level of capital and expertise. Jeito is uniquely positioned to do so, thanks to a proven, differentiated methodology and to a team with the experience to provide both financing and significant industry expertise.
